# A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

> **NCT03374085** · PHASE1,PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 200 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-92480
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03374085
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-06
- **Primary completion:** 2025-08-20
- **Final completion:** 2025-10-23
- **Target enrollment:** 200 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03374085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03374085, "A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03374085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*